AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation

AstraZeneca’s Imfinzi (durvalumab) and tremelimumab were granted Orphan Drug designation by the U.S. Food and Drug Administration as a possible treatment for hepatocellular carcinoma.